Reporting Germline Variants in Cancer Panels Could Provide Useful Info, but With Added Challenges | GenomeWeb

NEW YORK (GenomeWeb) – Cancer patients who undergo sequencing of their tumor genome may also benefit from an analysis of their germline DNA, although such analysis will also uncover clinically relevant findings not related to the patients' cancers and many variants of uncertain significance, according to researchers from Memorial Sloan Kettering Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.

Sponsored by

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.